T-cell lymphoma with CD30 expression ≥10% by IHC — qualifies for brentuximab vedotin-base...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-TCELL-CD30-POSITIVE`
Type	Red flag
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-AITL` `DIS-ALCL` `DIS-PTCL-NOS`
Sources	`SRC-ESMO-PTCL-2024` `SRC-NCCN-BCELL-2025`

Red Flag Origin

Definition	T-cell lymphoma with CD30 expression ≥10% by IHC — qualifies for brentuximab vedotin-based regimen (CHP-Bv per ECHELON-2)
Clinical direction	intensify
Category	high-risk-biology
Shifts algorithm	ALGO-PTCL-1L, ALGO-AITL-1L, ALGO-ALCL-1L, ALGO-MF-SEZARY-1L

Trigger Logic

{
  "any_of": [
    {
      "finding": "BIO-CD30-IHC",
      "value": "positive"
    },
    {
      "finding": "cd30_positive",
      "value": true
    }
  ],
  "type": "biomarker"
}

Notes

ALCL is universally CD30+; PTCL NOS / AITL ~40-60%. Brentuximab replaces vincristine in CHP backbone; ECHELON-2 showed superior outcomes vs standard CHOP. Funding pathway flag — brentuximab not НСЗУ-reimbursed.

Used By

Algorithms

ALGO-AITL-1L - ALGO-AITL-1L
ALGO-ALCL-1L - ALGO-ALCL-1L
ALGO-MF-SEZARY-1L - ALGO-MF-SEZARY-1L
ALGO-MF-SEZARY-2L - ALGO-MF-SEZARY-2L
ALGO-PTCL-1L - ALGO-PTCL-1L

Indications

IND-AITL-1L-CHOEP - IND-AITL-1L-CHOEP
IND-PTCL-1L-CHOEP-ALLOSCT - IND-PTCL-1L-CHOEP-ALLOSCT
IND-TCELL-1L-CHOEP - IND-TCELL-1L-CHOEP

Red flag

RF-PRIOR-BV-NAIVE - Patient has NOT previously received brentuximab vedotin (BV) — eligible for BV-containing...